Aemetis (NASDAQ:AMTX) Rating Reiterated by Truist Financial

Truist Financial reaffirmed their hold rating on shares of Aemetis (NASDAQ:AMTX) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $3.50 target price on the specialty chemicals company’s stock, down from their prior target price of $4.00.

AMTX has been the topic of several other research reports. StockNews.com upgraded Aemetis to a sell rating in a research note on Wednesday. HC Wainwright restated a buy rating and set a $28.00 target price on shares of Aemetis in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $12.13.

Aemetis Trading Down 6.4 %

AMTX stock opened at $2.49 on Wednesday. The stock has a 50-day moving average price of $3.26 and a 200-day moving average price of $3.69. Aemetis has a 1-year low of $2.29 and a 1-year high of $7.82. The firm has a market cap of $110.56 million, a PE ratio of -2.13 and a beta of 1.31.

Aemetis (NASDAQ:AMTX) last issued its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25). The business had revenue of $66.56 million during the quarter, compared to analysts’ expectations of $75.37 million. During the same period in the prior year, the company earned ($0.68) earnings per share. On average, analysts forecast that Aemetis will post -1.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director John R. Block sold 51,580 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $3.49, for a total transaction of $180,014.20. Following the completion of the sale, the director now owns 14,001 shares of the company’s stock, valued at $48,863.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aemetis

A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new stake in Aemetis in the 2nd quarter valued at $306,000. Rhumbline Advisers increased its holdings in Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after acquiring an additional 50,528 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Aemetis in the 1st quarter valued at $84,000. Finally, SG Americas Securities LLC bought a new stake in Aemetis in the 1st quarter valued at $60,000. Institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.